國立虎尾科技大學 |

Non-Biological Complex Drugs = The Science and the Regulatory Landscape /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Non-Biological Complex Drugs/ edited by Daan J.A. Crommelin, Jon S. B. de Vlieger.
其他題名:	The Science and the Regulatory Landscape /
其他作者:	Crommelin, Daan J.A.
面頁冊數:	IX, 390 p. 91 illus., 57 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmaceutical technology. -
電子資源:	https://doi.org/10.1007/978-3-319-16241-6
ISBN:	9783319162416

Non-Biological Complex Drugs = The Science and the Regulatory Landscape /
Non-Biological Complex DrugsThe Science and the Regulatory Landscape /[electronic resource] :edited by Daan J.A. Crommelin, Jon S. B. de Vlieger. - 1st ed. 2015. - IX, 390 p. 91 illus., 57 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,202210-7371 ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

Introduction: Defining the position of Non-Biological Complex Drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug Nanocrystals -- Analytical methods for determining the size (distribution) in parenternal dispersions -- NBCD Pharmacokinetics and Bioanalytical Methods to Measure Drug Release -- Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs -- Nanoparticle Albumin-Bound Anticancer Agents -- The EU regulatory landscape of Non-Biological Complex Drugs -- What did we learn? What can we expect in the future? Concluding remarks and outstanding issues.

The rise of bio- and nano-technology in the last decades has led to the emergence of a new and unique type of medicine known as non-biological complex drugs (NBCDs). This book illustrates the challenges associated with NBCD development, as well as the complexity of assessing the effects of manufacturing changes on innovator and follow-on batches of NBCDs. It also touches upon proven marketing authorization requirements for biosimilars that could be effective in evaluating follow-on NBCDs, including a demonstration of control over the manufacturing process and a need for detailed physico-chemical characterization and (pre)clinical tests. This book is meant to be used for years to come as a standard reference work for the development of NBCDs. Moreover, this book aims to stimulate discussions and further our thinking to ensure that decisions regarding the approval of complex drugs are made with relevant scientific data on the table. .

ISBN: 9783319162416

Standard No.: 10.1007/978-3-319-16241-6doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Non-Biological Complex Drugs = The Science and the Regulatory Landscape /
LDR:03193nam a22004215i 4500 001 960922
003 DE-He213
005 20200630221907.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319162416 $9 978-3-319-16241-6
024 7 $a 10.1007/978-3-319-16241-6 $2 doi
035 $a 978-3-319-16241-6
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Non-Biological Complex Drugs $h [electronic resource] : $b The Science and the Regulatory Landscape / $c edited by Daan J.A. Crommelin, Jon S. B. de Vlieger.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a IX, 390 p. 91 illus., 57 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20
505 0 $a Introduction: Defining the position of Non-Biological Complex Drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug Nanocrystals -- Analytical methods for determining the size (distribution) in parenternal dispersions -- NBCD Pharmacokinetics and Bioanalytical Methods to Measure Drug Release -- Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs -- Nanoparticle Albumin-Bound Anticancer Agents -- The EU regulatory landscape of Non-Biological Complex Drugs -- What did we learn? What can we expect in the future? Concluding remarks and outstanding issues.
520 $a The rise of bio- and nano-technology in the last decades has led to the emergence of a new and unique type of medicine known as non-biological complex drugs (NBCDs). This book illustrates the challenges associated with NBCD development, as well as the complexity of assessing the effects of manufacturing changes on innovator and follow-on batches of NBCDs. It also touches upon proven marketing authorization requirements for biosimilars that could be effective in evaluating follow-on NBCDs, including a demonstration of control over the manufacturing process and a need for detailed physico-chemical characterization and (pre)clinical tests. This book is meant to be used for years to come as a standard reference work for the development of NBCDs. Moreover, this book aims to stimulate discussions and further our thinking to ensure that decisions regarding the approval of complex drugs are made with relevant scientific data on the table. .
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Crommelin, Daan J.A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1255082
700 1 $a de Vlieger, Jon S. B. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1255083
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319162409
776 0 8 $i Printed edition: $z 9783319162423
776 0 8 $i Printed edition: $z 9783319358512
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-3-319-16241-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)